Radioembolization Therapy Market
Report ID: SQMIG35D2399
Report ID: SQMIG35D2399
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35D2399 |
Region:
Global |
Published Date: February, 2026
Pages:
157
|Tables:
90
|Figures:
78
Global Radioembolization Therapy Market size was valued at USD 1.30 Billion in 2024 and is poised to grow from USD 1.44 Billion in 2025 to USD 3.17 Billion by 2033, growing at a CAGR of 10.4% during the forecast period (2026-2033).
Rising incidence of liver cancer, growing demand for minimally invasive cancer treatments, advancements in targeted radiotherapy technologies, improvements in diagnostic imaging and dosimetry planning, and increasing clinical adoption of yttrium-90 microsphere therapies are driving demand for radioembolization therapy.
Technological advancements in imaging, catheter design, and personalized dosimetry planning have improved treatment precision and clinical outcomes. Increasing use of radioembolization as salvage therapy for chemotherapy-resistant colorectal liver metastases and as a bridge or downstaging strategy for hepatocellular carcinoma prior to liver transplantation is also supporting wider clinical adoption. Favorable reimbursement frameworks and expanding clinical research programs are further encouraging hospitals and cancer centers to invest in radioembolization technologies across global healthcare systems.
Evolution of radioembolization therapy from early experimental applications to widely adopted commercial solutions such as SIR-Spheres and TheraSphere is also creating a new business scope. Growing prevalence of primary and metastatic liver cancers around the world coupled with rising demand for targeted locoregional treatment approaches is expected to primarily drive radioembolization therapy market growth.
On the contrary, high treatment costs, complex procedural requirements, limited availability of trained interventional specialists, and strict regulatory and safety requirements related to radioactive materials are anticipated to slow down radioembolization therapy market penetration through 2033 and beyond.
How is AI Improving Treatment Precision In Radioembolization Therapy?
Precision in radioembolization therapy is being achieved through AI technologies that use advanced imaging techniques and machine learning capabilities for personalized treatment and procedure planning. The essential functions of precision radioembolization therapy include two main functions which are blood vessel segmentation and perfusion analysis together with AI dosimetry. Presently technology companies develop AI systems which they intend to use for standardizing imaging procedures and treatment planning methods in order to decrease differences that exist among medical professionals. The new technology development for radioembolization procedures establishes uniform procedures which medical professionals can trust because they will obtain consistent treatment results.
Market snapshot - (2026-2033)
Global Market Size
USD 1.3 Billion
Largest Segment
Radioactive Beads
Fastest Growth
Radioactive Beads
Growth Rate
10.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global radioembolization therapy market is segmented by device type, indication, end user, and region. Based on device type, the market is segmented into chemoembolization devices, radioactive beads, and delivery systems. Based on indication, the market is segmented into liver cancer, colorectal cancer, and other tumors. Based on end user, the market is segmented into hospitals, specialty clinics, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The radioactive beads segment is forecasted to spearhead the global radioembolization therapy market revenue generation in the long run. The capacity of these beads to deliver concentrated radioisotopes directly within tumor radioembolization, which helps it hold sway over others. This clinical fit has driven clinician preference, manufacturer focus, and repeatable procedural workflows, which together reinforce adoption, supplier investment, and ongoing refinement of bead properties and handling to support consistent therapeutic outcomes.
However, delivery systems are witnessing the strongest growth momentum as per this radioembolization therapy industry analysis. Improvements in catheter technology, imaging integration, and precision targeting enhance procedural safety and access, which expands application scope. The new technologies enable doctors to perform more difficult medical treatments and the innovations help more clinicians to use their capabilities and the manufacturers gain business prospects to create unified systems which will enable them to expand radiation therapy treatment options and increase treatment capacity.
The liver cancer segment is slated to account for the highest global radioembolization therapy market share in the future. Alignment of radioembolization with the organ-specific biology and vascular supply of primary hepatic tumors helps this segment maintain its dominant stance through 2033. That clinical alignment fosters strong referral patterns, guideline recognition, and institutional investment, which in turn motivate manufacturers and centers to optimize devices, training, and protocols to meet clinician expectations and ongoing patient demand.
On the other hand, colorectal cancer is emerging as the most rapidly expanding indication due to growing evidence supporting treatment of hepatic metastases and an uptick in combination approaches with systemic therapies. Expanding clinical research and evolving referral networks are driving broader use, prompting device adaptation and procedural innovation that create new opportunities for market growth and cross-disciplinary collaboration.
To get detailed segments analysis, Request a Free Sample Report
Presence of advanced clinical infrastructure, concentrated centers of excellence, and a mature medical device industry are also cementing the dominance of this region in terms of radioembolization therapy demand. Strong multidisciplinary care models link hepatology, oncology, and interventional radiology, which allows for efficient patient pathways and higher volumes of cases per physician. There is a large volume of clinical research and collaborative networks with industry that continuously refine clinical protocol and provide timely dissemination of best practices to advance quality and consistency of care.
Widespread availability of interventional oncology services concentrated in academic medical centers and specialized hospitals is shaping radioembolization therapy adoption in the United States. Comprehensive care pathways, combined with favorable reimbursement environments within prominent healthcare systems, further enhance service accessibility and procedural refinement. This is particularly so, considering the presence of research activities, imaging infrastructure, and commercial presence, thereby ensuring the continuous evolution of service delivery and accessibility.
Adoption of centralized healthcare decision making with provincial coordination is forecasted to influence radioembolization therapy demand across Canada. High emphasis on cost-effectiveness and evidence generation within the framework of public payers. There is an emphasis on access and integration with multidisciplinary liver cancer programs to increase procedural availability and align practice with national standards across Canada. Rising partnerships between specialized hospitals and provincial cancer agencies to support technology assessment is also creating new business scope.
Rise in availability of clinical evidence demonstrating therapeutic value and expansion of specialist interventional oncology centers drive steady radioembolization therapy demand in Europe. Collaborative efforts by regional organizations represent assistance with the development of standardized pathways and greater acceptance by clinicians; the development of health technology assessment (HTA) methods and availability of reimbursement models by both public and private payers; the practices of cross-border referrals and establishment of centers of excellence promoting knowledge transfers also create new business scope. Harmonization of regulatory processes and commercial partnerships are also expected to create new opportunities for radioembolization therapy vendors in the long run.
A dense network of specialized hospitals and a strong interventional radiology community are forecasted to boost radioembolization therapy demand in Germany. Centers of excellence in hospitals, comprehensive training of clinicians, and close collaboration with industry experts contribute to the development and refinement of the treatment. Reimbursement support and investments in hybrid operating rooms and imaging technologies support sustained procedure volumes. A well-developed local medtech industry and participation in clinical research contribute to innovation and expansion of services in the country’s healthcare ecosystem.
Expansion of specialist centers and structured evaluation frameworks within national health services are boosting radioembolization therapy adoption in the United Kingdom. Ongoing investments in facilities for interventional oncology and specialized training programs are enhancing practitioner competence and referral systems. There are close relationships between academic and regional facilities to share best practice. Health technology assessments and pilots are helping to spread the use of this treatment to specific facilities, promoting its integration into cancer treatment pathways.
High demand for proactive clinical research, regional centers of excellence, and supportive evaluation are boosting radioembolization therapy demand in France. Scaling of interventional radiology in various hospital networks is also predicted to boost radioembolization therapy adoption in the future. Increasing emphasis on evidence generation and coordinated referral processes are also creating new business scope for market players in the long run.
Asia Pacific is strengthening its position through targeted investment in cancer care infrastructure, expanding networks of tertiary hospitals and growing local expertise in interventional oncology. Regional manufacturers and international partnerships are increasing availability of devices and radiopharmaceuticals, supported by focused clinician training and technology transfer initiatives. Regulatory agencies in several markets are creating clearer pathways for device and therapy approval, while payers and hospitals are gradually recognizing the clinical value within multidisciplinary oncology programs. Cross border collaboration, participation in clinical studies and rising emphasis on advanced imaging and hybrid procedural suites are enhancing procedural capability and patient access across diverse healthcare systems in the region.
Presence of a sophisticated healthcare environment with strong imaging infrastructure and concentrated centers are shaping radioembolization therapy demand in Japan. Academic centers and research facilities play an important role in evidence generation and training of practitioners, which aids in assimilation into multidisciplinary treatment protocols for liver cancer. The approval system and hospital procurement routes ensure judicious introduction of new techniques, and working with centers and industry aids in post-market evaluation and optimization of procedures.
A network of high capability tertiary hospitals and a competitive private hospital sector are driving radioembolization therapy adoption across South Korea. Strong working relationships with industry and clinical trial activity will further enhance the capability and expertise in the country. Centralized models for referrals and investment in imaging and hybrid suites will further enhance the delivery of radioembolization therapy in the major metropolitan areas.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Prevalence Of Liver Tumors
Technological Advances In Therapies
High Procedural Costs and Logistics
Reimbursement and Policy Uncertainty
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in radioembolization is concentrated among legacy device makers, with M&A and targeted acquisitions reshaping supply and tech. Examples include Boston Scientific’s BTG acquisition for TheraSphere and Terumo’s acquisition of Quirem for holmium SIRT, while Sirtex advanced delivery platforms like SIROS and FLEXdose. Players pursue partnerships with radiopharma CDMOs and imaging vendors to secure supply chains and dosimetry differentiation.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, rising incidence of liver cancer and growing demand for minimally invasive targeted cancer treatments are anticipated to drive the demand for radioembolization therapy going forward. However, high treatment costs and complex procedural requirements are slated to slow down the adoption of radioembolization therapy in the future. North America is slated to spearhead the demand for radioembolization therapy owing to strong oncology treatment infrastructure and high adoption of advanced interventional radiology procedures. Development of AI-driven treatment planning tools and integration of advanced imaging and personalized dosimetry solutions are anticipated to be key trends driving the radioembolization therapy sector over the coming years.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.3 Billion |
| Market size value in 2033 | USD 3.17 Billion |
| Growth Rate | 10.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Radioembolization Therapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Radioembolization Therapy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Radioembolization Therapy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Radioembolization Therapy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Radioembolization Therapy Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.44 Billion in 2025 to USD 3.17 Billion by 2033, growing at a CAGR of 10.4% during the forecast period (2026-2033).
Competitive landscape in radioembolization is concentrated among legacy device makers, with M&A and targeted acquisitions reshaping supply and tech. Examples include Boston Scientific’s BTG acquisition for TheraSphere and Terumo’s acquisition of Quirem for holmium SIRT, while Sirtex advanced delivery platforms like SIROS and FLEXdose. Players pursue partnerships with radiopharma CDMOs and imaging vendors to secure supply chains and dosimetry differentiation. 'Evergreen Theragnostics: Established in 2019, their main objective is to provide domestic radiopharmaceutical contract development and manufacturing services to support theranostic and radioembolization supply chains. Recent development: the company completed a major financing round and broke ground on a US manufacturing facility to expand GMP production capacity, signed commercial agreements to accelerate clinical supply, and positioned itself as a regional CDMO for isotope and microsphere production.', 'RayzeBio: Established in 2020, their main objective is to develop targeted radiopharmaceutical conjugates for solid tumors with an emphasis on liver cancer. Recent development: the company advanced a GPC3 targeted program and entered a collaboration and out license with Ablaze Pharmaceuticals for Greater China development and commercialization, while progressing clinical candidate nomination for alpha and beta emitters aimed at liver tumor targets and building a North American clinical supply chain.', 'Boston Scientific Corporation', 'CeloNova BioSciences', 'Sensus Healthcare', 'Merz Pharmaceuticals', 'Biocompatibles', 'Sirtex Medical Limited', 'GRAIL, Inc.', 'Terumo Corporation', 'BTG International', 'Medtronic', 'ArcherDX', 'Curium', 'Nano-X Imaging', 'Varian Medical Systems', 'Elekta', 'Innova Medical', 'Epigenetics', 'AtriCure', 'GE Healthcare', 'Siemens Healthineers'
Rising prevalence of liver tumors increases clinical demand for targeted locoregional treatments and encourages healthcare providers to integrate radioembolization into care pathways. As more patients present with tumors unsuitable for surgery, clinicians seek alternatives that focus on tumor control while preserving liver function, prompting treatment center investment in equipment and staff training. Growing referral patterns and multidisciplinary collaboration further support adoption, as oncologists and interventional radiologists recognize therapeutic value. This expanding patient pool and clinical endorsement collectively stimulate market uptake and service expansion.
Precision Patient Selection: Growing emphasis on refined patient stratification and individualized treatment planning is driving demand for radioembolization. Clinicians and centers are prioritizing multidisciplinary evaluation, advanced imaging interpretation, and biomarker informed decisions to identify suitable candidates and optimize outcomes. This focus enhances perceived treatment value, supports adoption in complex care pathways, and encourages development of provider training and decision support tools. Market uptake is increasingly influenced by demonstrated clinical appropriateness and procedural alignment with personalized oncology strategies, strengthening stakeholder confidence and referral patterns.
Why does North America Dominate the Global Radioembolization Therapy Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
